# Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

> **NCT06475989** · PHASE3 · RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 264 (estimated)

## Conditions studied

- Refractory Differentiated Thyroid Gland Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dabrafenib
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Questionnaire Administration
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT06475989
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2030-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475989, "Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06475989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*